NCT07046156View on ClinicalTrials.gov

Treatment of Overactive Bladder With Anticholinergic Agents

Active, not recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 1, 2026

Conditions
Overactive Bladder
Interventions
DRUG

Oxybutynin Cl

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

DRUG

propiverine

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

DRUG

Tolterodine

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Trial Locations (1)

Unknown

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

OTHER